Drug Discovery Outsourcing Services Market-By Service Type (Chemistry, Biological), Dug Type (Small & Large-molecule), Disease Model (In-vitro, Cellular & Animal Models), Therapeutic Area (Diabetes, Neurology, Oncology), Global Forecast (2023-2032)

List of Tables

Drug Discovery Outsourcing Services Market size is poised to record 8.2% CAGR from 2023-2032, on account of the rapid advances in biologics, including gene therapies and monoclonal antibodies.

The surging developments in novel biologics and personalized medicine solutions to cater to individual patients is leading to the greater demand for outsourcing services in biopharmaceutical R&D activities. To cite an instance, in January 2021, Charles River Laboratories International partnered with biopharma service provider JADE Biomedical to expand its global biologics testing capabilities while accommodating the demand for biologics therapeutics, mainly cell and gene therapies. The growing focus of outsourcing providers on services, such as real-world evidence generation as well as patient-centric trial designs for improved efficiency of clinical research will also contribute to the market growth.

The drug discovery outsourcing services industry is segmented based on service type, drug type, disease model, therapeutic area, and region.

In terms of service type, the market size from the chemistry services segment will record appreciable CAGR from 2023-2032. Drug discovery outsourcing chemistry services are playing pivotal role in the pharmaceutical and biotechnology industries in streamlining and expediting the drug development process. The surging importance of outsourcing computational chemistry services to cater to uses in virtual screening, molecular modeling, and structure-based drug design will also contribute to the segment growth.

On the basis of therapeutic area, the drug discovery outsourcing services industry value from the neurology segment is projected to expand up to 2032. The growth can be attributed to the higher burden of Alzheimer's disease, Parkinson's disease, and multiple sclerosis along with the subsequent need for the development of their effective treatments. Accelerated R&D activities, reduces costs, and the improved access to specialized expertise are some advantages of outsourcing neurology drug discovery services.

Regionally, the APAC drug discovery outsourcing services market size is projected to observe notable CAGR through 2032 due to the presence of large talent pools, cost-effective labor, and favorable regulatory environments. The surging need for reducing costs, accessing specialized expertise, and accelerating the drug development process has compelled numerous pharmaceutical and biotechnology companies to turn to outsourcing for drug discovery services. The evolving regulatory landscape related to intellectual property, clinical trials, and data security will also add to the regional industry growth.

Product Code: 6632

Chapter 1 Methodology & Scope

1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Drug discovery outsourcing services industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Service type trends
- 2.1.4 Drug type trends
- 2.1.5 Disease model trends
- 2.1.6 Therapeutic area trends

Chapter 3 Drug Discovery Outsourcing Services Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of chronic diseases globally
  - 3.2.1.2 Increasing demand for outsourcing novel drugs and therapeutics
  - 3.2.1.3 Increasing R&D expenditure by pharmaceutical and biotechnology companies
  - 3.2.1.4 Increasing technological advancements in drug discovery
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Intellectual property concerns
3.3 Growth potential analysis
- 3.3.1 By service type
- 3.3.2 By drug type
- 3.3.3 By disease model
- 3.3.4 By therapeutic area
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
- 3.5.1 U.S.
- 3.5.2 Europe
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
- 4.1.1 Pharmaceutical Product Development (Thermo Fisher Scientific, Inc.)
- 4.1.2 Laboratory Corporation of America Holdings (Covance Inc.)
- 4.1.3 IQVIA (Quintiles IMS Holdings, Inc.)
- 4.1.4 Eurofins Scientific
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategy dashboard, 2022

Chapter 5 Drug Discovery Outsourcing Services Market, By Service Type, 2018 - 2032 (USD Million)

5.1 Key trends, by service type
5.2 Chemistry services
5.3 Biological services

Chapter 6 Drug Discovery Outsourcing Services Market, By Drug Type, 2018 - 2032 (USD Million)

6.1 Key trends, by drug type
6.2 Small-molecule drugs
6.3 Large-molecule drugs

Chapter 7 Drug Discovery Outsourcing Services Market, By Disease Model, 2018 - 2032 (USD Million)

7.1 Key trends, by disease model
7.2 In vitro models
7.3 Animal models
7.4 Cellular models
7.5 Other disease models

Chapter 8 Drug Discovery Outsourcing Services Market, By Therapeutic Area, 2018 - 2032 (USD Million)

8.1 Key trends, by therapeutic area
8.2 Diabetes
8.3 Neurology
8.4 Oncology
8.5 Infectious diseases
8.6 Other therapeutic areas

Chapter 9 Drug Discovery Outsourcing Services Market, By Region, 2018 - 2032 (USD Million)

9.1 Key trends, by region
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East & Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

10.1 Charles River Laboratories International, Inc.
10.2 IQVIA (Quintiles IMS Holdings, Inc.)
10.3 Laboratory Corporation of America Holdings (Covance Inc.)
10.4 Pharmaceutical Product Development (Thermo Fisher Scientific, Inc.)
10.5 WuXi AppTec
10.6 Eurofins Scientific
10.7 GenScript ProBio (Genscript Biotech Corporation)
10.8 Aragen Life Sciences Ltd.
10.9 Syngene International Limited
10.10 Aurigene Pharmaceutical Services Ltd.
10.11 Pharmaron
10.12 Shanghai ChemPartner
10.13 Jubilant Biosys Ltd (Jubilant Pharmova Limited)